Company News

CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS. Following a successful research collaboration, King’s College London selected the system to create a unique human-relevant liver-intestinal model for characterizing and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, CN Bio’s next-generation Multi-Organ MPS combines their industry-proven in vitro 3D liver model with a range of other organs, to provide a flexible in vitro human-relevant alternative to animals that facilitates the investigation of inter-organ cross talk effects. Read more

Related stories

Read More

Park member Gearset is featured in Business Weekly, with CEO Kevin Boyle reflecting on the company’s journey from startup to ...

Read More

Park member Xampla has featured on BBC Radio Cambridgeshire for the second time in as many months, reflecting growing interest ...

Read More

Park innovator Eco-Inject has secured £5.2 million in equity funding, led by Adjuvo. The investment will enable Eco-Inject to scale ...

Want to see your news featured here? Contact the team and let’s spread the word.